

# Yang Ge

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4720187/yang-ge-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28

papers

228

citations

9

h-index

14

g-index

30

ext. papers

383

ext. citations

5.7

avg, IF

2.94

L-index

#	Paper	IF	Citations
28	Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/ECatenin activity and cancer stemness.. <i>Cancer Letters</i> , <b>2022</b> , 531, 83-83	9.9	2
27	Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma.. <i>Translational Oncology</i> , <b>2022</b> , 17, 101317	4.9	1
26	Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	0
25	Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 739263	5.3	0
24	Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer. <i>Cancer Cell International</i> , <b>2021</b> , 21, 552	6.4	2
23	DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 1980-1991	6.6	1
22	Regorafenib plus PD-1 inhibitors in Chinese patients with microsatellite stable/mismatch repair proficient metastatic colorectal cancer: A real-world study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e15585-e15585	2.2	0
21	Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 640099	5.6	0
20	Geographic heterogeneity in the outcomes of patients receiving immune checkpoint inhibitors for advanced solid tumors: a meta-analysis.. <i>Translational Cancer Research</i> , <b>2021</b> , 10, 310-326	0.3	
19	Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro. <i>Journal of Clinical Laboratory Analysis</i> , <b>2021</b> , 35, e23986	3	3
18	Development and Validation of a Prognostic Gene Signature Correlated With M2 Macrophage Infiltration in Esophageal Squamous Cell Carcinoma.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 769727	5.3	6
17	Reverse engineering a predictive signature characterized by proliferation, DNA damage, and immune escape from stage I lung adenocarcinoma recurrence. <i>Acta Biochimica Et Biophysica Sinica</i> , <b>2020</b> , 52, 638-653	2.8	1
16	Disruption of Core 1-mediated O-glycosylation oppositely regulates CD44 expression in human colon cancer cells and tumor-derived exosomes. <i>Biochemical and Biophysical Research Communications</i> , <b>2020</b> , 521, 514-520	3.4	10
15	Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer. <i>Life Sciences</i> , <b>2020</b> , 241, 117150	6.8	13
14	The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy. <i>International Immunopharmacology</i> , <b>2020</b> , 88, 106972	5.8	11
13	Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. <i>International Immunopharmacology</i> , <b>2020</b> , 87, 106770	5.8	2
12	DCLK1 Plays a Metastatic-Promoting Role in Human Breast Cancer Cells. <i>BioMed Research International</i> , <b>2019</b> , 2019, 1061979	3	13

11	Implications for Tumor Microenvironment and Epithelial Crosstalk in the Management of Gastrointestinal Cancers. <i>Journal of Oncology</i> , <b>2019</b> , 2019, 4835318	4.5	2
10	The efficacy of dietary Spirulina as an adjunct to chemotherapy to improve immune function and reduce myelosuppression in patients with malignant tumors.. <i>Translational Cancer Research</i> , <b>2019</b> , 8, 1065-1073	0.3	4
9	Short-term clinical outcomes of enteral nutrition versus parenteral nutrition after surgery for pancreatic cancer: a meta-analysis.. <i>Translational Cancer Research</i> , <b>2019</b> , 8, 1403-1411	0.3	
8	Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 1162-1175	7.5	33
7	RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 2018, 4248971	2.8	22
6	Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells. <i>Molecular Cancer</i> , <b>2017</b> , 16, 30	42.1	51
5	Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase. <i>Cancer Research</i> , <b>2016</b> , 76, 4090-9	10.1	22
4	Abstract 577: Systemic delivery of CBT-15G DCLK1-targeted monoclonal antibody dramatically decreases tumorigenesis in a xenograft model of pancreatic cancer <b>2016</b> ,		3
3	Hepatic radiofrequency ablation causes an increase of circulating histones in patients with hepatocellular carcinoma. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2015</b> , 75, 621-7	2	5
2	Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line. <i>OncoTargets and Therapy</i> , <b>2015</b> , 8, 1603-10	4.4	9
1	Novel Molecular Regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in NSCLC Cells. <i>Clinical Laboratory</i> , <b>2015</b> , 61, 1855-63	2	7